Arbutus Biopharma Corp Q2 FY2023 earnings call

Bill Collier discussed Arbutus' goal to develop a functional cure for chronic Hepatitis B, highlighting progress with imdusiran (AB-729), which impacts surface antigen and HBV-specific immune response, with sustained effects in some patients. Announced CTA approval for phase 1 clinical trial of AB-101 in New Zealand while addressing FDA concerns. Karen Sims reviewed phase 2A combination trials with imdusiran, including one with Vaccitech's VTP-300 and expansion to include low-dose nivolumab. Mentioned ongoing phase 1 trial for AB-161 and progress on COVID-19 antiviral AB-343 with IND enabling studies planned for H2 2023.

No specific financial performance data for product segments provided in the transcript.

Plan to initiate phase 1 clinical trial with AB-101 in New Zealand this quarter. Expect to report initial data from AB-729 phase 2A combination trial with Vaccitech in H2 2023. Anticipate initial data from AB-161 phase 1 single ascending dose study in H2 2023. Aim to complete IND enabling studies for AB-343 and nominate nsp12 candidate in H2 2023.

Forward-looking statements subject to risks described in recent SEC filings, including Form 10-K, 10-Q, and other documents. Uncertainties in clinical trial timelines and outcomes for HBV and COVID-19 programs.

Q: From a big picture perspective around Hepatitis B, how should investors think about this space given challenges and long study timelines?

A: Bill Collier stated the strategy of reducing HBV DNA, suppressing surface antigen, and boosting immune system is correct, with combination trials to find functional cure, expecting data to establish a benchmark.

Q: How else can Arbutus leverage the SRNA platform?

A: Bill and David Hastings mentioned being well-capitalized, royalty monetization, and cautious spending on combination trials.

Q: When can we expect the next data set from the AB-729 phase 2A study?

A: Bill Collier said updates will be provided in January 2024.

Q: Details on AB-101 phase 1 trial?

A: Initiating in New Zealand, an umbrella study including healthy subjects and chronic Hepatitis B patients.

Q: What data can we expect from AB-161?

A: Karen Sims said early data will be on safety, with pharmacodynamic data in HBV patients later.

Q: Update on coronavirus antiviral AB-343?

A: Mike Sofia mentioned continuing work with partners, slow process in China, but ongoing efforts.